Hollevoet K - Search Results

1

Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.

Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodríguez Portal JA, Schneider J, Muley T, Di Serio F, Baas P, Tomasetti M, Rai AJ, van Meerbeeck JP. Hollevoet K, et al. J Clin Oncol. 2012 May 1;30(13):1541-9. doi: 10.1200/JCO.2011.39.6671. Epub 2012 Mar 12. J Clin Oncol. 2012. PMID: 22412141 Free PMC article. Review.

2

Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.

Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP. Hollevoet K, et al. Am J Respir Crit Care Med. 2010 Mar 15;181(6):620-5. doi: 10.1164/rccm.200907-1020OC. Epub 2010 Jan 14. Am J Respir Crit Care Med. 2010. PMID: 20075387

3

Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study.

Hollevoet K, Van Cleemput J, Thimpont J, De Vuyst P, Bosquée L, Nackaerts K, Germonpré P, Vansteelandt S, Kishi Y, Delanghe JR, van Meerbeeck JP. Hollevoet K, et al. J Thorac Oncol. 2011 May;6(5):889-95. doi: 10.1097/JTO.0b013e31820db377. J Thorac Oncol. 2011. PMID: 21358346 Free article.

4

Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.

Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquée L, De Vuyst P, Germonpré P, Kellen E, Legrand C, Kishi Y, Delanghe JR, van Meerbeeck JP. Hollevoet K, et al. J Thorac Oncol. 2011 Nov;6(11):1930-7. doi: 10.1097/JTO.0b013e3182272294. J Thorac Oncol. 2011. PMID: 21841505 Free article.

5

The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.

Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpré P, De Vuyst P, Bosquée L, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP. Hollevoet K, et al. Chest. 2012 Feb;141(2):477-484. doi: 10.1378/chest.11-0129. Epub 2011 Jul 7. Chest. 2012. PMID: 21737491

6

Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorption.

Hollevoet K, Speeckaert MM, Decavele AS, Vanholder R, van Meerbeeck JP, Delanghe JR. Hollevoet K, et al. Clin Lung Cancer. 2012 Nov;13(6):470-4. doi: 10.1016/j.cllc.2011.12.004. Epub 2012 Mar 2. Clin Lung Cancer. 2012. PMID: 22386954 Clinical Trial.

7

Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum.

Hollevoet K, Bernard D, De Geeter F, Walgraeve N, Van den Eeckhaut A, Vanholder R, Van de Wiele C, Stove V, van Meerbeeck JP, Delanghe JR. Hollevoet K, et al. Clin Chem. 2009 Jul;55(7):1431-3. doi: 10.1373/clinchem.2008.121913. Epub 2009 Apr 30. Clin Chem. 2009. PMID: 19406915 Free article. No abstract available.

8

Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers.

Sharon E, Zhang J, Hollevoet K, Steinberg SM, Pastan I, Onda M, Gaedcke J, Ghadimi BM, Ried T, Hassan R. Sharon E, et al. Among authors: hollevoet k. Clin Chem Lab Med. 2012 Apr;50(4):721-5. doi: 10.1515/CCLM.2011.816. Clin Chem Lab Med. 2012. PMID: 22149739 Free PMC article.

9

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.

Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I. Hassan R, et al. Among authors: hollevoet k. Cancer. 2014 Nov 1;120(21):3311-9. doi: 10.1002/cncr.28875. Epub 2014 Jul 2. Cancer. 2014. PMID: 24989332 Free PMC article. Clinical Trial.

10

DNA-Based Delivery of Checkpoint Inhibitors in Muscle and Tumor Enables Long-Term Responses with Distinct Exposure.

Jacobs L, De Smidt E, Geukens N, Declerck P, Hollevoet K. Jacobs L, et al. Among authors: hollevoet k. Mol Ther. 2020 Apr 8;28(4):1068-1077. doi: 10.1016/j.ymthe.2020.02.007. Epub 2020 Feb 13. Mol Ther. 2020. PMID: 32101701 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters